Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ruzasvir · AT-038, MK-8408

Small molecule · developed by Atea Pharmaceuticals

Phase 2 Most advanced trial (none active)
AVIR Developer
2 Registered trials

What is Ruzasvir?

Ruzasvir (also known as AT-038 and MK-8408) is an orally administered agent studied in chronic hepatitis C virus infection, including patients with hepatic cirrhosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AT-038, MK-8408
Drug type
Small molecule
Therapy area
Gastroenterology, Infectious disease
Developer
Atea Pharmaceuticals, Inc. (AVIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
LX752BD95Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05904470 Phase 2 Chronic Hepatitis C Virus Completed AVIR
NCT05731843 Phase 1 Healthy Volunteer Study Completed AVIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis C VirusHCVHealthy Volunteer StudyHepatic CirrhosisHepatitis CHepatitis C, Chronic

More from Atea Pharmaceuticals

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVIR page.

Follow AVIR, the company behind Ruzasvir

See AVIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.